APVO NASDAQ
Aptevo Therapeutics Inc.
1W: -5.8%
1M: -31.5%
3M: -60.2%
YTD: -81.0%
1Y: -92.9%
3Y: -100.0%
5Y: -100.0%
$1.76
+0.00 (+0.00%)
Weekly Expected Move ±7.3%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (22)
Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock Short Interest Rises 59.0%
Aptevo Therapeutics (NASDAQ:APVO) Share Price Passes Below 50 Day Moving Average – Should You Sell?
Aptevo Therapeutics reports Q2 results
Aptevo Therapeutics (NASDAQ:APVO) Shares Cross Below 50 Day Moving Average – Here’s What Happened
APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement
APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Up 18.8% in March
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why
Aptevo Therapeutics GAAP EPS of -$87.27
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Decline in Short Interest
12 Health Care Stocks Moving In Wednesday's Intraday Session
10 Health Care Stocks Moving In Monday's Pre-Market Session
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Drop in Short Interest
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Drops By 86.5%
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
What's Going On With Aptevo Therapeutics Stock Today?
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now